This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In his written submission to the Health and Social Care Committee , O’Callaghan had the audacity to attack Professor Mike Barnes, based on a scurrilous article in the tabloid Mail on Sunday, for his “significant financial interests in the cannabis industry”. Read full article: [link].
In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients. More rigorous clinicaltrials are needed to establish clear guidelines for its use in MS management.
Data collected from MAPS-sponsored Phase 3 clinicaltrials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. View original article. With a goal of determining the “the efficacy of marijuana in treating the medical conditions of United States armed services veterans and preventing veteran suicide.”.
In this comprehensive article, we’ll delve into the potential benefits and challenges of using MMJ as a treatment for epilepsy, as well as share the perspectives of both medical professionals and patients who have experienced the promising effects of MMJ on seizure control and overall well-being.
Using a content analysis approach, we investigated articles about medicinal cannabis from 2000 to the end of 2019 in the Medical Journal of Australia, Australian Doctor , Medical Observer , Australian Journal of General Practice , Australian Family Physicia n , and Australian Medicine. Conclusions. Background.
CAS Article Google Scholar. Article Google Scholar. Article Google Scholar. Article Google Scholar. Article Google Scholar. Article Google Scholar. Article Google Scholar. CAS Article Google Scholar. Article Google Scholar. Article Google Scholar.
Mr. Gardner, the writer whose CBD advocacy eventually inspired the 2011 summit at Ms. fast-tracked clinicaltrials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. There haven’t been enough clinicaltrials and there never will be,” said Mr. Clarke, the cannabis seed collector. Read the full article here.
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinicaltrials and international studies. Healing Advocacy Fund. Rick Doblin, Ph.D, in/rickdoblin/ [link]. in/andrew-chadeayne-989b751/ [link]. Sam Chapman.
In this article, we will explore the ongoing effort to reschedule marijuana from a Schedule I to a Schedule III drug and explain the upcoming December hearing process, detailing the promises and challenges ahead. drug policy and public opinion regarding cannabis’ status as a medicine.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content